Published in
Elsevier, The Lancet Oncology, 4(21), p. 497-507, 2020
DOI: 10.1016/s1470-2045(19)30862-9
Links
Tools
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Journal article published in 2020 by
Chiara Cremolini 
,
Alberto Zaniboni,
Carlotta Antoniotti,
Daniele Rossini,
Sara Lonardi,
Fotios Loupakis,
Filippo Pietrantonio,
Roberto Bordonaro,
Tiziana Pia Latiano,
Emiliano Tamburini ,
Daniele Santini,
Alessandro Passardi,
Federica Marmorino,
Roberta Grande,
Giuseppe Aprile
and other authors.
,
Alberto Zaniboni,
Carlotta Antoniotti,
Daniele Rossini,
Sara Lonardi,
Fotios Loupakis,
Filippo Pietrantonio,
Roberto Bordonaro,
Tiziana Pia Latiano,
Emiliano Tamburini ,
Daniele Santini,
Alessandro Passardi,
Federica Marmorino,
Roberta Grande,
Giuseppe Aprile
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 